Regeneron agrees with U.S. government to lower drug prices and offers new gene therapy free in the U.S.

Baird's international and global growth funds underperform MSCI benchmarks in Q2 2026.

In Q2 2026, Baird's Chautauqua International Growth Fund returned +10.39%, trailing the MSCI ACWI ex-U.S. Index's +14.49%. Key detractors included Alibaba and Lululemon, while Recruit and ASML contributed positively. The Global Growth Fund also lagge...